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analysis revealed that if both utilities were tested at the
high or low end of their ranges, they were no longer 
sensitive. CONCLUSIONS: Both drugs, given their low
potential for drug-drug interactions, time-released for-
mulations, and lack of anticholinergic side effects, are
appropriate for use in the elderly and may improve
overall quality of life. However, the results suggest that
bupropion SR may be a more cost-effective choice of anti-
depressant pharmacotherapy in an elderly population,
particularly in patients concerned about potential adverse
sexual side effects.
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OBJECTIVE: To quantify differences in resource utiliza-
tion and healthcare cost between olanzapine and risperi-
done when used as augmentation agents in patients with
depression. METHODS: We conducted a retrospective
analysis using the California Medicaid database (Medi-
Cal 1996–2000). Adult patients aged 18 to 65 with 1 year
of continuous enrollment and one or more medical claims
for depression were included in the analysis. Patients 
with schizophrenia or psychotic depression were
excluded. Treatment groups consisted of patients who
received augmentation with risperidone or olanzapine
after completing at least four weeks of antidepressant
treatment. Cost comparisons were made using the
amount paid by Medi-Cal to providers over the six-
month period following the initiation of antidepressant
treatment. RESULTS: Risperidone (N = 105) and olan-
zapine (N = 130) groups were similar with respect to
length of treatment, use of antidepressants, and occur-
rence and number of outpatient and inpatient visits.
Mean antipsychotic costs per month were signiﬁcantly
lower for risperidone ($154.31 vs. $258.13, p < 0.0001).
A signiﬁcantly higher proportion of risperidone subjects
(62.9% vs. 39.2% for olanzapine) had total mental
healthcare costs that were below the median (p = 0.0003).
CONCLUSIONS: Relative to olanzapine, augmentation
with risperidone was associated with signiﬁcantly lower
antipsychotic and total mental health costs.
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OBJECTIVES: To compare the costs and effectiveness 
of Methadone Maintenance Treatment (MMT) and
Buprenorphine Maintenance Treatment (BMT) among
stabilized opioid dependent patients. METHODS: A cost
analysis was performed. One hundred forty-ﬁve patients,
on either treatment between 1 month and 12 months,
were selected from 28 randomly chosen community phar-
macies. Questionnaires were issued to 135 community
pharmacies, of which 67 (including these 28) validly
responded for costing these 2 services. (24 of the phar-
macies did not provide either of these services.) A treat-
ment sector perspective was chosen. Costs incurred at the
Commonwealth government, pharmacy and patient levels
were investigated. ANOVA models were applied to test
for differences while controlling for length on program.
Effectiveness was measured as change in opioid-free days.
RESULTS: At the Commonwealth government level,
costs of the medicines and doctor visits were taken into
account. The estimated monthly cost (SD) per methadone
patient was AUD$62.8 ($32.6) and AUD$169.0 ($33.7)
per buprenorphine patient. Costs of medicines comparing
treatments showed a signiﬁcant difference (p = 0.000) but
doctor visits showed none (p = 0.609). At the pharmacy
level, the estimated monthly cost (SD) of one MMT
patient was AUD$104.3 ($24.5) and AUD$128.2 ($40.3)
per BMT patient (p = 0.005). At the patient level, median
monthly fees (range) for dispensing and transportation
were $128.0 ($61.3–$234.7) per MMT patient whereas
$156.0 ($66.0–$394.7) per BMT patient. The difference
lay in the monthly transportation fee (p = 0.008). During
the ﬁrst year of treatment, estimated mean total cost (SD)
on one MMT patient was $306.2 ($51.2) monthly, but
$465.8 ($66.4) for one BMT patient (p = 0.000). The
average change in opioid-free days (SD) out of 30 was
27.7 (5.7) days for MMT, and 26.0 (7.2) days for BMT
patients (p = 0.102). CONCLUSIONS: Signiﬁcant differ-
ences in costs of MMT and BMT were identiﬁed. MMT
was less costly but resulted in the same overall change in
opioid-free days.
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OBJECTIVE: To determine the economic impact of an
appropriate use edit placed on select non-benzodiazepine
hypnotic agents for an HMO client. METHOD: Zolpi-
dem and zaleplon are non-benzodiazepine hypnotics indi-
cated for the short-term treatment of insomnia, generally
7–10 days. Comparator HMO 1, with approximately
380,000 members, instituted an appropriate use edit
allowing for 14 days of hypnotic therapy every 3 months.
Comparator HMO 2, with approximately 220,000
members, placed no edit and served as the control. The
study time frame was January–December 2000. Phar-
macy claims data were used to evaluate the effect of the
edit by identifying the number of prescriptions ﬁlled, the
